Does the media prefer TGTX or AGIO?

In the previous week, TG Therapeutics had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 8 mentions for TG Therapeutics and 6 mentions for Agios Pharmaceuticals. TG Therapeutics' average media sentiment score of 0.99 beat Agios Pharmaceuticals' score of 0.90 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COGT or AGIO?

In the previous week, Cogent Biosciences had 6 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 12 mentions for Cogent Biosciences and 6 mentions for Agios Pharmaceuticals. Cogent Biosciences' average media sentiment score of 1.27 beat Agios Pharmaceuticals' score of 0.90 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGON or AGIO?

In the previous week, CG Oncology had 10 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 16 mentions for CG Oncology and 6 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat CG Oncology's score of 0.13 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or MIRM?

In the previous week, Mirum Pharmaceuticals had 22 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 6 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat Mirum Pharmaceuticals' score of 0.64 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or SRRK?

In the previous week, Scholar Rock had 14 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 20 mentions for Scholar Rock and 6 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat Scholar Rock's score of -0.01 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Agios Pharmaceuticals (AGIO) Competitors

$33.32 -0.15 (-0.44%)

As of 03:09 PM Eastern

Compare

AGIO vs. TGTX, COGT, CGON, MIRM, and SRRK

Should you buy Agios Pharmaceuticals stock or one of its competitors? Agios Pharmaceuticals's main competitors and comparable companies include TG Therapeutics (TGTX), Cogent Biosciences (COGT), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Agios Pharmaceuticals compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

TG Therapeutics presently has a consensus target price of $63.00, suggesting a potential upside of 29.76%. Agios Pharmaceuticals has a consensus target price of $41.25, suggesting a potential upside of 23.78%. Given TG Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe TG Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

TG Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	12.06	$447.18M	$2.74	17.72
Agios Pharmaceuticals	$54.03M	36.82	-$412.78M	-$7.01	N/A

TG Therapeutics has a net margin of 55.22% compared to Agios Pharmaceuticals' net margin of -418.24%. TG Therapeutics' return on equity of 73.49% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, TG Therapeutics had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 8 mentions for TG Therapeutics and 6 mentions for Agios Pharmaceuticals. TG Therapeutics' average media sentiment score of 0.99 beat Agios Pharmaceuticals' score of 0.90 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Agios Pharmaceuticals on 14 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Cogent Biosciences has higher earnings, but lower revenue than Agios Pharmaceuticals. Cogent Biosciences is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Agios Pharmaceuticals	$54.03M	36.82	-$412.78M	-$7.01	N/A

Cogent Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Cogent Biosciences presently has a consensus target price of $49.10, indicating a potential upside of 30.41%. Agios Pharmaceuticals has a consensus target price of $41.25, indicating a potential upside of 23.78%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cogent Biosciences is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cogent Biosciences has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-86.42%	-48.97%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

In the previous week, Cogent Biosciences had 6 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 12 mentions for Cogent Biosciences and 6 mentions for Agios Pharmaceuticals. Cogent Biosciences' average media sentiment score of 1.27 beat Agios Pharmaceuticals' score of 0.90 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cogent Biosciences beats Agios Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Agios Pharmaceuticals has a net margin of -418.24% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -26.58% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-26.58%	-25.34%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

In the previous week, CG Oncology had 10 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 16 mentions for CG Oncology and 6 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat CG Oncology's score of 0.13 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology currently has a consensus price target of $83.18, suggesting a potential upside of 10.85%. Agios Pharmaceuticals has a consensus price target of $41.25, suggesting a potential upside of 23.78%. Given Agios Pharmaceuticals' higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

CG Oncology has higher earnings, but lower revenue than Agios Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,646.42	-$160.99M	-$2.69	N/A
Agios Pharmaceuticals	$54.03M	36.82	-$412.78M	-$7.01	N/A

Summary

CG Oncology beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Mirum Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Agios Pharmaceuticals currently has a consensus target price of $41.25, suggesting a potential upside of 23.78%. Mirum Pharmaceuticals has a consensus target price of $137.33, suggesting a potential upside of 36.39%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	36.82	-$412.78M	-$7.01	N/A
Mirum Pharmaceuticals	$521.31M	12.54	-$23.36M	-$14.55	N/A

Agios Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -139.18% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

In the previous week, Mirum Pharmaceuticals had 22 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 6 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat Mirum Pharmaceuticals' score of 0.64 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Agios Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Scholar Rock?

Agios Pharmaceuticals (NASDAQ:AGIO) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Agios Pharmaceuticals currently has a consensus target price of $41.25, suggesting a potential upside of 23.78%. Scholar Rock has a consensus target price of $57.71, suggesting a potential upside of 9.94%. Given Agios Pharmaceuticals' higher probable upside, research analysts plainly believe Agios Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

In the previous week, Scholar Rock had 14 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 20 mentions for Scholar Rock and 6 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.90 beat Scholar Rock's score of -0.01 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agios Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Scholar Rock has lower revenue, but higher earnings than Agios Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	36.82	-$412.78M	-$7.01	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Scholar Rock has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Scholar Rock	N/A	-159.92%	-90.71%

91.1% of Scholar Rock shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Scholar Rock beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.00B	$3.71B	$6.99B	$13.03B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-4.77	10.52	269.55	25.26
Price / Sales	36.82	1,290.58	597.75	101.23
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.94	17.50	13.08	6.33
Net Income	-$412.78M	-$13.32M	$3.45B	$347.70M
7 Day Performance	3.27%	1.53%	1.02%	0.97%
1 Month Performance	-16.52%	1.39%	1.68%	0.92%
1 Year Performance	-9.15%	55.83%	67.42%	20.45%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	2.5912 of 5 stars	$33.32 -0.4%	$41.25 +23.8%	-8.6%	$2.00B	$54.03M	N/A	390
TGTX TG Therapeutics	4.3832 of 5 stars	$49.16 -1.2%	$63.00 +28.2%	+72.0%	$7.62B	$616.29M	17.94	290
COGT Cogent Biosciences	2.3958 of 5 stars	$41.53 -2.0%	$45.90 +10.5%	+211.4%	$7.24B	N/A	N/A	80	Positive News Earnings Report Analyst Forecast
CGON CG Oncology	2.4562 of 5 stars	$76.56 +1.9%	$83.18 +8.6%	+182.0%	$6.66B	$4.04M	N/A	61
MIRM Mirum Pharmaceuticals	3.5295 of 5 stars	$98.70 -1.9%	$137.33 +39.1%	+51.6%	$6.54B	$521.31M	N/A	140	Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. TGTX, COGT, CGON, MIRM, and SRRK

How does Agios Pharmaceuticals compare to TG Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Cogent Biosciences?

Summary

How does Agios Pharmaceuticals compare to CG Oncology?

Summary

How does Agios Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Agios Pharmaceuticals compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. TGTX, COGT, CGON, MIRM, and SRRK

How does Agios Pharmaceuticals compare to TG Therapeutics?

Do analysts rate TGTX or AGIO?

Which has more volatility & risk, TGTX or AGIO?

Which has higher earnings and valuation, TGTX or AGIO?

Is TGTX or AGIO more profitable?

Do institutionals & insiders hold more shares of TGTX or AGIO?

Does the media prefer TGTX or AGIO?

Summary

How does Agios Pharmaceuticals compare to Cogent Biosciences?

Which has higher earnings & valuation, COGT or AGIO?

Which has more volatility and risk, COGT or AGIO?

Do analysts prefer COGT or AGIO?

Is COGT or AGIO more profitable?

Does the media prefer COGT or AGIO?

Summary

How does Agios Pharmaceuticals compare to CG Oncology?

Do insiders and institutionals have more ownership in CGON or AGIO?

Which has more risk & volatility, CGON or AGIO?

Is CGON or AGIO more profitable?

Does the media refer more to CGON or AGIO?

Do analysts rate CGON or AGIO?

Which has higher earnings & valuation, CGON or AGIO?

Summary

How does Agios Pharmaceuticals compare to Mirum Pharmaceuticals?

Do analysts prefer AGIO or MIRM?

Which has higher valuation and earnings, AGIO or MIRM?

Which has more risk & volatility, AGIO or MIRM?

Is AGIO or MIRM more profitable?

Does the media favor AGIO or MIRM?

Summary

How does Agios Pharmaceuticals compare to Scholar Rock?

Do analysts recommend AGIO or SRRK?

Does the media favor AGIO or SRRK?

Which has more risk and volatility, AGIO or SRRK?

Which has higher earnings & valuation, AGIO or SRRK?

Is AGIO or SRRK more profitable?

Do insiders & institutionals believe in AGIO or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools